Xtandi Does Not Increase Seizure Rates in At-Risk mCRPC Patients, Study Finds

Xtandi Does Not Increase Seizure Rates in At-Risk mCRPC Patients, Study Finds
A safety study that looked at the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) found that the therapy does not increase seizure rates for those who have seizure risk factors. The study, “Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure,” was published in the journal JAMA Oncology. Xtandi is an androgen receptor inhibitor shown to be effective in treating patients with mCRPC. However, seizures are a known adverse effect of the drug. Various clinical trials have reported patients experiencing seizures while on the treatment. No previous trials had evaluated Xtandi's safety for patients with seizure risk factors. Prompted by requests from the U.S. Food and Drug Administration and the European Medicines Agency, the UPWARD Phase 4 study (NCT01977651) examined Xtandi's effect on men with seizure risk factors. The prospective international safety study took place from September 2013 to February 2016. Participants had at least one risk factor for seizures at baseline, such as medications that lower the seizure threshold, history of stroke, or history of seizures. Patients who had a seizure and required anti-seizure medication within the past 12 months were excluded. Participants were treated with 160 mg of oral Xtandi per day. The study's primary objective was to learn the proportion of patients who
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *